Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: Tumor-reducing effects on hormone-sensitive prostate cancer in rats

Anti-Cancer Drugs

Volumn 16, Issue 8, 2005, Pages 855-861

  Abramjuk, Claudia ^a   Jung, Klaus ^a   Krell, Hans Willi ^b   Juchem, Rolf ^b   Peters, Robert ^a   Taymoorian, Kasra ^a   Staack, Andrea ^a   Stephan, Carsten ^a   Schnorr, Joerg ^a   Loening, Stefan A ^a   Lein, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Dunning tumor; Magnetic resonance imaging; Matrix metalloproteinase inhibitor; Prostate cancer; Rat

Indexed keywords

ANDROGEN; ESTRAMUSTINE; MATRIX METALLOPROTEINASE INHIBITOR; RO 282653; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; HORMONE SENSITIVITY; IN VIVO STUDY; MALE; METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; RAT; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTRAMUSTINE; MALE; MATRIX METALLOPROTEINASES; NEOPLASMS, HORMONE-DEPENDENT; PIPERAZINES; PROSTATIC NEOPLASMS; PYRIMIDINES; RATS; RATS, INBRED STRAINS; SURVIVAL RATE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 24044521336     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000173477.05358.ec     Document Type: Article

References (36)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Pirtskhalaishvili G, Hrebinko RL, Nelson JB. The treatment of prostate cancer: an overview of current options. Cancer Pract 2001; 9:295-306.
3. Klein EA, Kupelian PA. Localized prostate cancer: radiation or surgery? Urol Clin North Am 2003; 30:315-330, ix.
4. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999; 26:407-421.
5. Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003; 29:171-187.
6. Lucia MS, Bostwick DG, Bosland M, Cockett AT, Knapp DW, Leav I, et al. Workgroup I: rodent models of prostate cancer. Prostate 1998; 36:49-55.
7. Lubaroff DM, Canfield L, Reynolds CW. The Dunning tumors. Prog Clin Biol Res 1980; 37:243-263.
8. Lein M, Jung K, Ortel B, Stephan C, Rothaug W, Juchem R, et al. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 2002; 21:2089-2096.
9. Mangoldt D, Sinn B, Lein M, Krell HW, Schnorr D, Loening SA, et al. The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells. Apoptosis 2002; 7:217-220.
10. Jung K, Krell HW, Ortel B, Hasan T, Romer A, Schnorr D, et al. Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats. Prostate 2003; 54:206-211.
11. Maquoi E, Sounni NE, Devy L, Olivier F, Frankenne F, Krell HW, et al. Antiinvasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4, 6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 2004; 10:4038-4047.
12. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51:5054s-5059s.
13. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-174.
14. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2:657-672.
15. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999; 31:34-45.
16. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13:781-792.
17. Roeb E, Dietrich CG, Winograd R, Arndt M, Breuer B, Fass J, et al. Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9. Cancer 2001; 92: 2680-2691.
18. Kanoh Y, Akahoshi T, Ohara T, Ohtani N, Mashiko T, Ohtani S, et al. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res 2002; 22: 1813-1817.
19. Harnacher S, Matern S, Roeb E. [Extracellular matrix-from basic research to clinical significance. An overview with special consideration of matrix metalloproteinases]. Dtsch Med Wochenschr 2004; 129:1976-1980.
20. Lein M, Jung K, Le DK, Hasan T, Ortel B, Borchert D, et al. Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate 2000; 43:77-82.
21. Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986; 9:261-281.
22. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003; 98:2592-2598.
23. Albrecht W, Van Poppel H, Horenblas S, Mickisch G, Horwich A, Serretta V, et al. Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer 2004; 90:100-105.
24. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58:1048-1051.
25. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11: S37-S43.
26. Lambert V, Munaut C, Jost M, Noel A, Werb Z, Foidart JM, et al. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am J Pathol 2002; 161:1247-1253.
27. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15:61-75.
28. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93:178-193.
29. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295:2387-2392.
30. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets 2003; 7:385-397.
31. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003; 22:177-203.
32. Andarawewa KL, Boulay A, Masson R, Mathelin C, Stoll I, Tomasetto C, et al. Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res 2003; 63:5844-5849.
33. Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003; 35:252-257.
34. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004; 48:411-424.
35. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003; 532:91-107.
36. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003; 89:1817-1821.